Wednesday, November 25, 2009, 5:19am EST - Canadian Markets open in 4 hours and 11 minutes.
To create a watchlist or portfolio of shares, Sign-in or Register

SciClone Pharmaceuticals, Inc. (SCLN)

 On Nov 24: 2.49 USD   0.00 (0.00%)  
MORE ON SCLN
Quotes
HereSummary
Charts
News & Info
Company
Analyst Coverage
Ownership
Financials
SciClone Pharmaceuticals, Inc. (NGM:SCLN) Delayed quote dataEdit
Last Trade: 2.49 USD
Trade Time: Nov 24
Change: 0.00 (0.00%)
Prev Close: 2.49
Open: N/A
Bid: 2.35 x 100
Ask: 2.95 x 400
1y Target Est: 5.50
Day's Range: N/A - N/A
52wk Range: 0.63 - 5.33
Volume: 0
Avg Vol (3m): 564,623
Market Cap: 117.54M
P/E (ttm): N/A
EPS (ttm): -0.17
Div & Yield: N/A (N/A%)
SciClone Pharmaceuticals, Inc. (SCLN)
1d  5d  3m  6m  1y  2y  5y  max 
 Add SCLN to Portfolio   Download Data

HEADLINES
• BioMed News Bytes: Transcept, ProUroCare, SciClone, ABIO
at Seeking Alpha (Tue 10:31am)
• SciClone Announces Enrollment Completion in Phase 2 Oral Mucositis Trial of SCV-07
Marketwire (Mon, Nov 23)
• SciClone Pharmaceuticals to Present at the Piper Jaffray Annual Healthcare Conference
Marketwire (Mon, Nov 23)
• SCICLONE PHARMACEUTICALS INC Financials
EDGAR Online Financials (Fri, Nov 13)
• SciClone Pharmaceuticals Announces Presentations of SCV-07 Data at Upcoming Medical Meetings
Marketwire (Thu, Nov 12)
• SCICLONE PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements
EDGAR Online (Mon, Nov 9)
• SciClone Pharmaceuticals, Inc. Earnings Call scheduled for 8:30 am ET today
CCBN (Mon, Nov 9)
• UPDATE - SciClone Q3 tops estimates, raises '09 view
at Reuters (Mon, Nov 9)
• Q3 2009 SciClone Pharmaceuticals, Inc. Earnings Release - Time Not Supplied
CCBN (Mon, Nov 9)
• SciClone Reports Financial Results and Provides Commercial and Pipeline Updates for the Third Quarter of 2009
Marketwire (Mon, Nov 9)
• SCICLONE PHARMACEUTICALS INC Files SEC form 8-K, Amendment or Waiver to Code of Ethics, Financial Statements and Exhi
EDGAR Online (Fri, Nov 6)
More Headlines for SCLN...
ANALYST
EPS Est (next year) (Dec-07) : N/A
EPS Est (in 2 years) (Dec-08) : N/A
Avg Rec (current)*: 2.0
PEG Ratio: N/A
* (Strong Buy) 1.0 - 5.0 (Strong Sell)
Analyst Opinion - Estimates

BUSINESS SUMMARY
SciClone Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of therapeutics to treat life-threatening diseases.

Full Company Profile

Add to My Portfolio Add to Portfolio    Email to a Friend Email to a Friend
Get Summary for Another Symbol:
Symbol Lookup
• Latest News • Canadian Indices